key: cord-0891819-vqtjuenm
authors: Weir, Robin A P; Glen, Claire; McDowell, Kirsty
title: ACE-2 downregulation and incidence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection
date: 2020-11-18
journal: Am J Hypertens
DOI: 10.1093/ajh/hpaa191
sha: be1d00d409236117b2291b1c18f0c2c276c398b7
doc_id: 891819
cord_uid: vqtjuenm

nan

The effect of chronically downregulated ACE-2 on susceptibility to SARS-CoV-2 is unknown. There is a signal that inhibiting ACE-2 might be beneficial. Anti-ACE-2 antibodies inhibited SARS-CoV-1 replication in animal models, as did the specific ACE-2-inhibitor N-(2-aminoethil)-1 aziridine-ethamine. 3 The direct renin antagonist aliskiren downregulates ACE-2 in rodent models. 4 The authors' dataset includes over 300 000 patients with detailed medication prescription records; could they provide data on prescription of aliskiren and, if numbers sufficient, incident SARS-CoV-2 infection, hospitalisations and outcomes in those receiving aliskiren? If incidence and hospitalisation rate is reduced, this could inform a paradigm shift in focus from ACE-2 amelioration to antagonism in the prevention/limitation of future ACE-2 mediated viral infections including SARS-CoV-2.

A c c e p t e d M a n u s c r i p t

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

Aliskiren inhibits angiotensin II/angiotensin 1-7(Ang II/Ang1-7) signal pathway in rats with diabetic nephropathy